Parkinson’s disease Flashcards
What is it?
Progressive disorder of central nervous system, which is due to dopamine depletion
Risk factors
Male gender
Genetic component
Environmental exposure to insecticides, pesticides and herbicides
Pathophysiology
Decrease in dopamine producing cells in pars compacta region of the substantia nigra
Dopamine produced is secreted to the Putamen and Caudate nucleus
Increase in lewy bodies in substantia nigra
Where is substantia nigra
Midbrain
Signs and symptoms
Facial TRAPS Face - expressionless Tremor (Resting tremor) Rigidity Akinesia Postural instability Shuffling gait
Investigations
No specific test - clinical diagnosis:
CT scan and MRI scan may be arranged but these are usually normal
PET, SPECT and Ioflupane (DaTSCAN) may measure basal ganglia dopaminergic function
Conservative treatment
Patient education
Rehabilitation to improve gait and mobility
Regular assessment of activities of daily living
Medical treatment
Levodopa
Carbidopa
Selegiline
Amantadine
Surgical treatment
This option is unlikely, due to improvements in medical treatment
Complications
Dysphagia
Dementia
Increased risk of falls
Erectile dysfunction
Physiology of levodopa
Crosses the blood-brain barrier (BBB) where it is converted to dopamine
Physiology of carbidopa
Always given with levodopa
It is a dopa decarboxylase inhibitor
Prevents levodopa being metabolised to dopamine in other regions of the body
Thus acts to decrease peripheral side effects
Physiology of selegiline
inhibits monoamine oxidase B (MAO-B)
this enzyme breaks down dopamine
Physiology of amantadine
dopamine agonist
decreases symptoms of Parkinsons
What is it
Degenerative movement disorder caused by a REDUCTION IN DOPAMINE in the SUBSTANTIA NIGRA